<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drug\PMC7249615\results\search\drug\results.xml">
  <result pre="new treatment strategies for COVID-19: is there a role for" exact="bromhexine" post="as add-on therapy? DepfenhartMarkusdr@drdepfenhart.de12de VilliersDanielle3LemperleGottfried4MeyerMarkus5Di SommaSalvatore67[1], [2], [3], [4],"/>
  <result pre="on SARS-CoV-2 have brought attention to the possible benefit of" exact="chloroquine" post="in the treatment of patients infected by SARS-CoV-2. Whether"/>
  <result pre="chloroquine in the treatment of patients infected by SARS-CoV-2. Whether" exact="chloroquine" post="can treat SARS-CoV-2 alone and also work as a"/>
  <result pre="a protease inhibitor or a competitive virus ACE2-binding inhibitor. Using" exact="bromhexine" post="at a dosage that selectively inhibits TMPRSS2 and, in"/>
  <result pre="to be effective against SARS-CoV-2. We propose the use of" exact="bromhexine" post="as a prophylactic and treatment. We encourage the scientific"/>
  <result pre="prophylactic and treatment. We encourage the scientific community to assess" exact="bromhexine" post="clinically as a prophylactic and curative treatment. If proven"/>
  <result pre="accessible, and cost-effective application worldwide. Keywords SARS-CoV-2 COVID-19 Prophylactic Treatment" exact="Bromhexine" post="Protease inhibitor Background â€œPandemic is not a word to"/>
  <result pre="since entry of the virus into cells was reduced by" exact="camostat" post="mesilate, a TMPRSS2 inhibitor. It is currently only approved"/>
  <result pre="could be a potential treatment option of CoV infections [29]." exact="Nafamostat" post="mesilate is also a serine protease inhibitor widely used"/>
  <result pre="pancreatic and kidney disease. It is structurally closely related to" exact="camostat" post="mesilate. Researchers previously identified nafamostat mesilateâ€™s potential to inhibit"/>
  <result pre="is structurally closely related to camostat mesilate. Researchers previously identified" exact="nafamostat" post="mesilateâ€™s potential to inhibit MERS-CoV [30]. Risks of complications"/>
  <result pre="cough suppressants, as a potential TMPRSS2 inhibitor for their application." exact="Bromhexine" post="is orally readily bioavailable. Endonasal application is also a"/>
  <result pre="readily bioavailable. Endonasal application is also a good alternative option." exact="Bromhexine" post="is an over-the-counter (OTC) drug [32] that is affordable"/>
  <result pre="are highly dependent on the endosomal pathway and particularly pH." exact="Chloroquine" post="(N4-(7-chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine), an FDA-approved drug, [36] has been used to"/>
  <result pre="malaria for many years, [37] as well as autoimmune diseases." exact="Chloroquine" post="is known to block virus infection by increasing endosomal"/>
  <result pre="release of viral DNA or RNA into the cytosol. Moreover," exact="chloroquine" post="has immunomodulatory effects, suppressing the production/release of TNF-Î±, IL-1Î²,"/>
  <result pre="with viral infection and replication. A combination of remdesivir and" exact="chloroquine" post="was proven to effectively inhibit the recently emerged SARS-CoV-2"/>
  <result pre="to effectively inhibit the recently emerged SARS-CoV-2 in vitro [41]." exact="Chloroquine" post="and hydroxychloroquine (HCQ) have been found to be efficient"/>
  <result pre="inhibit the recently emerged SARS-CoV-2 in vitro [41]. Chloroquine and" exact="hydroxychloroquine" post="(HCQ) have been found to be efficient against SARS-CoV-2,"/>
  <result pre="and reported to be efficient in Chinese COVID-19 patients [42]." exact="Chloroquine" post="is easily available and relatively low in cost. Therefore,"/>
  <result pre="is potentially clinically applicable against COVID-19. However, an overdose of" exact="chloroquine" post="can cause acute poisoning and death [43]. HCQ sulfate,"/>
  <result pre="derivative of chloroquine, demonstrated much less (~ 40%) toxicity than" exact="chloroquine" post="in animals [44] and is a good alternative. As"/>
  <result pre="will go hand-in-hand with partial loss of this lung protection." exact="Chloroquine" post="and the less toxic HCQ are of particular importance"/>
  <result pre="activity is inhibited by an elevated endosomal pH and, thus," exact="chloroquine" post="treatment will also work [52]. Interference with viral replication"/>
  <result pre="Interference with RNA-dependent RNA polymerase Remdesivir (GS-5734) is a 1â€²-cyano-substituted" exact="adenosine" post="nucleotide analog prodrug (RNA-dependent RNA polymerase inhibitor) and shows"/>
  <result pre="drug moleculesâ€™ docking study of the 3CLpro pocket indicates that" exact="chloroquine" post="and bromhexine have high binding affinity to 3CLpro [61]."/>
  <result pre="docking study of the 3CLpro pocket indicates that chloroquine and" exact="bromhexine" post="have high binding affinity to 3CLpro [61]. Interestingly, quercetin"/>
  <result pre="has a strong binding affinity for 3CLpro, greater than both" exact="bromhexine" post="and chloroquine, and thus, all three drugs are inhibitors"/>
  <result pre="of becoming infected or transmitting the virus from being reached." exact="Bromhexine" post="or bromhexine hydrochloride (N-cyclo-N-methyl-(2-amino-3,5-dibromo-benzyl) amine hydrochloride) is derived from"/>
  <result pre="infected or transmitting the virus from being reached. Bromhexine or" exact="bromhexine" post="hydrochloride (N-cyclo-N-methyl-(2-amino-3,5-dibromo-benzyl) amine hydrochloride) is derived from Vasicin, a"/>
  <result pre="vasica, and is a brominated aniline and benzylamine derivative [62]." exact="Bromhexine" post="hydrochloride acts as a mucolytic (breaks down mucus and"/>
  <result pre="characterized by low side effects and a low purchase price." exact="Bromhexine" post="is structurally related to ambroxol, an active demethylated metabolite"/>
  <result pre="medicine in the market. The available data suggest further that" exact="ambroxol" post="is a potent inducer of surfactant synthesis in AT2"/>
  <result pre="the potential as an adjuvant in anti-infective therapy [64]. Thus," exact="bromhexine" post="also provides indirect protective effects. Bromhexine hydrochloride is sold"/>
  <result pre="anti-infective therapy [64]. Thus, bromhexine also provides indirect protective effects." exact="Bromhexine" post="hydrochloride is sold under a few brand names, such"/>
  <result pre="the package inserts (information for use), the medicinal products containing" exact="bromhexine" post="hydrochloride are usually administered three times a day (8â€&quot;16Â"/>
  <result pre="times higher in pulmonary parenchyma compared to plasma concentrations. Unchanged" exact="bromhexine" post="is bound to plasma proteins by 95% [66, 67]."/>
  <result pre="cancer using TMPRSS2 inhibitors. The extent of metastasis reduction with" exact="bromhexine" post="was slightly lower in the wild-type mice than in"/>
  <result pre="in the study (72Â h) [31]. The terminal half-life of" exact="bromhexine" post="in an oral application of 8Â mg per single"/>
  <result pre="per single dose is an average of 6.6Â h [67]." exact="Bromhexine" post="is orally readily bioavailable, and thus, a more frequent"/>
  <result pre="the first pass effect. Laporte and Naesens [68] reported that" exact="bromhexine" post="did not show any significant cell entry or replication"/>
  <result pre="these results are not representative for SARS-CoV-2 [68]. In theory," exact="bromhexine" post="is an attractive drug against COVID-19, because it is"/>
  <result pre="off-label use. The IC90 (inhibitory concentration) for TMPRSS2 inhibition using" exact="bromhexine" post="is favorable at 1Â Î¼mol compared to 10Â Î¼mol"/>
  <result pre="is favorable at 1Â Î¼mol compared to 10Â Î¼mol for" exact="camostat" post="mesilate. However, the first pass effect for bromhexine is"/>
  <result pre="Î¼mol for camostat mesilate. However, the first pass effect for" exact="bromhexine" post="is much higher than for camostat mesilate (75â€&quot;80% versus"/>
  <result pre="first pass effect for bromhexine is much higher than for" exact="camostat" post="mesilate (75â€&quot;80% versus 33â€&quot;40%). The currently recommended oral dose"/>
  <result pre="mesilate (75â€&quot;80% versus 33â€&quot;40%). The currently recommended oral dose for" exact="camostat" post="mesilate is 300â€&quot;600Â mg per day which would translate"/>
  <result pre="body-based preliminary exploratory randomized-controlled clinical study on treating COVID-19 with" exact="bromhexine" post="hydrochloride tablets (BHT). The clinical study evaluated the efficacy"/>
  <result pre="for the experimental group and 66.67% for the control group)." exact="Bromhexine" post="and ambroxol appear to have a liver protective effect."/>
  <result pre="experimental group and 66.67% for the control group). Bromhexine and" exact="ambroxol" post="appear to have a liver protective effect. Comparatively, liver"/>
  <result pre="The exploratory results of the study support our proposal that" exact="bromhexine" post="hydrochloride may have a good effect on the treatment"/>
  <result pre="on COVID-19 have brought attention to the possible benefit of" exact="chloroquine" post="in the treatment of patients infected by SARS-CoV-2. Whether"/>
  <result pre="chloroquine in the treatment of patients infected by SARS-CoV-2. Whether" exact="chloroquine" post="can treat COVID-19 alone and also work as a"/>
  <result pre="poisoned and one death has occurred due to overdose using" exact="chloroquine" post="[69]. The FDA does say that studies are under"/>
  <result pre="does say that studies are under way to see if" exact="chloroquine" post="can be effective in the treatment of COVID-19. Chloroquine"/>
  <result pre="if chloroquine can be effective in the treatment of COVID-19." exact="Chloroquine" post="had been approved for â€œcompassionate useâ€� where patients are"/>
  <result pre="where patients are in a life-threatening condition. Past research on" exact="chloroquine" post="has shown in vitro activity against many different viruses,"/>
  <result pre="many different viruses, but no benefit in animal models [70]." exact="Chloroquine" post="in almost all animal models of different viral infections"/>
  <result pre="only partially worked or did not work [71â€&quot;73]. Treatment with" exact="chloroquine" post="did not prevent influenza infection in a randomized, double-blind,"/>
  <result pre="virus replication. This may explain the recent success reported with" exact="chloroquine" post="to assist in the curing of the virus. In"/>
  <result pre="has to contain, at least, either a TMPRSS2 inhibitor, e.g.," exact="bromhexine" post="or a competitive virus ACE2-binding inhibitor, e.g., a peptide"/>
  <result pre="the hostâ€™s body. Furthermore, a combination with the lesser toxic" exact="chloroquine" post="derivate, HCQ sulfate, that is (amongst other functions) an"/>
  <result pre="the following 4Â days [78]. The toxic dosage range of" exact="chloroquine" post="and HCQ is close to the therapeutic range [79]."/>
  <result pre="HCQ is close to the therapeutic range [79]. Especially, since" exact="chloroquine" post="derivatives are quite toxic, a combination with bromhexine and"/>
  <result pre="Especially, since chloroquine derivatives are quite toxic, a combination with" exact="bromhexine" post="and a lower dose of HCQ could be applicable."/>
  <result pre="same could be applicable for the herein proposed drug application." exact="Bromhexine" post="would be a valuable addition in combination with antivirals"/>
  <result pre="how we can exploit these mechanisms to treat SARS-CoV-2 using" exact="bromhexine" post="and/or hydroxychloroquine (HCQ) and/or quercetin. SARS-CoV-2 employs two routes"/>
  <result pre="can exploit these mechanisms to treat SARS-CoV-2 using bromhexine and/or" exact="hydroxychloroquine" post="(HCQ) and/or quercetin. SARS-CoV-2 employs two routes for host"/>
  <result pre="was put forward for the repurposing of existing drugs namely" exact="bromhexine" post="in combination with HCQ and/or quercetin as an immediately"/>
  <result pre="already existing approved drug to be used for off-label usage." exact="Bromhexine" post="or preferably in combination with HCQ could be such"/>
  <result pre="of the disease. We encourage the scientific community to test" exact="bromhexine" post="and the suggested combinations and to follow our recommended"/>
  <result pre="clinical study project, entitled â€œEvaluating the Efficacy and Safety of" exact="Bromhexine" post="Hydrochloride Tablets Combined with Standard Treatment/ Standard Treatment in"/>
  <result pre="protocol for a randomized controlled trial on the assessment of" exact="camostat" post="treatment in chronic pancreatitis (TACTIC)Trials201920150110.1186/s13063-019-3606-y31412955 29.ZhouYVedanthamPLuKAgudeloJCarrionRNunneleyJWet al.Protease inhibitors targeting"/>
  <result pre="inhibitors targeting coronavirus and filovirus entryAntiviral Res2015116768410.1016/j.antiviral.2015.01.01125666761 30.YamamotoMMatsuyamaSLiXTakedaMKawaguchiYInoueJ-Iet al.Identification of" exact="nafamostat" post="as a potent inhibitor of middle east respiratory syndrome"/>
  <result pre="(2020) Antiandrogens. https://www.drugs.com/drug-class/antiandrogens.html. Accessed 14 Apr 2020 36.Sanofi-Synthelabo Inc. (2001)" exact="Chloroquine" post="FDA label. https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB00608.pdf?1265922797. Accessed 22 Mar 2020 37.AguiarACCMurceECortopassiWAPimentelASAlmeidaMBarrosDCSet al.Chloroquine"/>
  <result pre="a novel class of autophagy inhibitorsNeurosurg Focus201538E1210.3171/2014.12.FOCUS1474825727221 41.WangMCaoRZhangLYangXLiuJXuMet al.Remdesivir and" exact="chloroquine" post="effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in"/>
  <result pre="emerged novel coronavirus (2019-nCoV) in vitroCell Res202030326927110.1038/s41422-020-0282-032020029 42.GautretPLagierJCParolaPHoangVTMeddedLMailheMet al.Hydroxychloroquine and" exact="Azithromycin" post="as a treatment of COVID-19: preliminary results of an"/>
  <result pre="toxicity of chloroquine1979GenevaWorld Health Organization 44.McChesneyEWAnimal toxicity and pharmacokinetics of" exact="hydroxychloroquine" post="sulfateAm J Med1983751a111810.1016/0002-9343(83)91265-26408923 45.ZhangHPenningerJMLiYZhongNSlutskyASAngiotensin-converting enzyme 2 (ACE2) as a"/>
  <result pre="51.FrlanRGobecSInhibitors of cathepsin BCurr Med Chem2006132309232710.2174/09298670677793512216918357 52.SchrezenmeierEDornerTMechanisms of action of" exact="hydroxychloroquine" post="and chloroquine: implications for rheumatologyNat Rev Rheumatol202016315516610.1038/s41584-020-0372-x32034323 53.AgostiniMLAndresELSimsACGrahamRLSheahanTPLuXet al.Coronavirus"/>
  <result pre="Thorac Soc201512576577410.1513/AnnalsATS.201411-507FR25742123 64.PlomerMde ZeeuwJMore than expectorant: new scientific data on" exact="ambroxol" post="in the context of the treatment of bronchopulmonary diseasesMMW"/>
  <result pre="bronchopulmonary diseasesMMW Fortschritte der Medizin2017159Suppl 5223310.1007/s15006-017-9805-028643291 65.GaoXHuangYHanYBaiC-XWangGThe protective effects of" exact="Ambroxol" post="in Pseudomonas aeruginosa-induced pneumonia in ratsArch Med Sci20117340541310.5114/aoms.2011.2340322312374 66.Boehringer"/>
  <result pre="Fearing coronavirus, Arizona man dies after taking a form of" exact="chloroquine" post="used to treat aquariums. CNN Health. https://edition.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html. Accessed 30"/>
  <result pre="aquariums. CNN Health. https://edition.cnn.com/2020/03/23/health/arizona-coronavirus-chloroquine-death/index.html. Accessed 30 Mar 2020. 70.TouretFde LamballerieXOf" exact="chloroquine" post="and COVID-19Antiviral Res202017710476210.1016/j.antiviral.2020.10476232147496 71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of chloroquine"/>
  <result pre="LamballerieXOf chloroquine and COVID-19Antiviral Res202017710476210.1016/j.antiviral.2020.10476232147496 71.KeyaertsELiSVijgenLRysmanEVerbeeckJVan RanstMet al.Antiviral activity of" exact="chloroquine" post="against human coronavirus OC43 infection in newborn miceAntimicrob Agents"/>
  <result pre="OC43 infection in newborn miceAntimicrob Agents Chemother20095383416342110.1128/aac.01509-0819506054 72.TanYWYamWKSunJChuJJHAn evaluation of" exact="chloroquine" post="as a broad-acting antiviral against hand, foot and mouth"/>
  <result pre="against hand, foot and mouth diseaseAntiviral Res201814914314910.1016/j.antiviral.2017.11.01729175128 73.YanYZouZSunYLiXXuK-FWeiYet al.Anti-malaria drug" exact="chloroquine" post="is highly effective in treating avian influenza A H5N1"/>
  <result pre="a randomised, double-blind, placebo controlled trialLancet Infect Dis201111967768310.1016/S1473-3099(11)70065-221550310 75.ShimizuYYamamotoSHommaMIshidaNEffect of" exact="chloroquine" post="on the growth of animal virusesArchiv fÃ¼r die gesamte"/>
  <result pre="vitro antiviral activity and projection of optimized dosing design of" exact="hydroxychloroquine" post="for the treatment of severe acute respiratory syndrome coronavirus"/>
 </snippets>
</snippetsTree>
